RXi Pharmaceuticals Corporation (RXII) ended last trading session with a change of 7.62 percent. It trades at an average volume of 950.68K shares versus 3.91M shares recorded at the end of last trading session. The share price of $0.85 is at a distance of 41.7 percent from its 52-week low and down -74 percent versus its peak. The company has a market cap of $5.92M and currently has 6.96M shares outstanding. The share price is currently 17.21 percent versus its SMA20, 19.99 percent versus its SMA50, and -47.18 percent versus its SMA200. The stock has a weekly performance of 23.22 percent and is 18.96 percent year-to-date as of the recent close.
February 23, 2017 — RXi Pharmaceuticals Corp.’s (RXII) proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It’s no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi’s President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort.
Fate Therapeutics, Inc. (FATE) recently recorded 5.21 percent change and currently at $5.05 is 243.54 percent away from its 52-week low and down -3.81 percent versus its peak. It has a past 5-day performance of 21.1 percent and trades at an average volume of 251.00K shares. The stock has a 1-month performance of 71.77 percent and is 101.2 percent year-to-date as of the recent close. There were about 39.15M shares outstanding which made its market cap $197.71M. The share price is currently 27.46 percent versus its SMA20, 53.79 percent versus its SMA50, and 92.39 percent versus its SMA200.
On March 13, 2017 Fate Therapeutics, Inc. (FATE) announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for FATE-NK100, the Company’s first-in-class adaptive memory natural killer (NK) cell product candidate. The Company expects a first-in-human clinical trial of FATE-NK100 for advanced acute myeloid leukemia (AML) to open enrollment at the Masonic Cancer Center, University of Minnesota following approval of the Center’s institutional review board.